Weight Loss Clinic in Wigston
Mounjaro and Wegovy, prescribed by a GPhC-registered Independent Prescriber and dispensed on-site. Three miles from Wigston, free initial consultation.
Real weight loss, prescribed properly — three miles from Wigston.
Wigston residents don't need to wait months for an NHS weight management referral or pay city-centre clinic prices to access GLP-1 medication. Clarendon Pharmacy on Welford Road runs a pharmacist-led weight loss clinic just three miles from Wigston — around ten minutes by car up the A5199, with free patient parking on-site.
Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines that need a qualified prescriber. The clinic is led by Mohammed Kolia (MPharm, IP), a GPhC-registered Independent Prescriber, which means we can assess, prescribe, dispense and review your treatment all in one place. No relay through a GP, no separate online prescriber sitting in another city.
Treatment starts with a free, no-obligation consultation. We'll check your BMI, run through your medical history, your goals, and confirm whether GLP-1 treatment is clinically appropriate. NICE recommends these medicines for adults with a BMI of 30 or above (or 27.5 if you have a weight-related condition like type 2 diabetes, hypertension, or sleep apnoea).
After your first prescription you'll book back monthly for a check-in — weight, side effects, dose escalation if appropriate, and your next month's supply. Most patients see clear progress within 12–16 weeks. No subscription, no contract — you stop when you're ready.
GLP-1 weight loss treatment for Wigston residents
Wigston is the largest catchment area south of Leicester city centre. The local demographic is broad — commuters, families, retirees, healthcare workers — and weight management need is widespread. NHS Tier 3 weight-management services covering Wigston have 12–24 month waiting lists and strict eligibility thresholds (typically BMI 35+, or 32.5+ with comorbidity). For adults who meet NICE eligibility (BMI 30+, or 27.5+ with weight-related condition) but want to start within weeks rather than years, private GLP-1 treatment is the practical route.
Clarendon Pharmacy is three miles north of Wigston, about ten minutes up the A5199 / Saffron Lane. Mohammed Kolia (MPharm, IP) is a GPhC-registered Independent Prescriber, which means assessment, prescription, dispensing and monthly reviews all happen in one place — no relay through GP, no separate online prescriber in another city.
How do Mounjaro and Wegovy work?
Both drugs mimic GLP-1, a hormone naturally released after eating that signals fullness to the brain and slows stomach emptying. Mounjaro additionally acts on GIP (glucose-dependent insulinotropic polypeptide), a second appetite-regulating hormone — it's a dual GLP-1/GIP agonist. In practice:
- You feel full sooner, on smaller meals.
- You feel hungry less often between meals.
- Food cravings (especially for high-calorie, high-reward foods) reduce significantly.
- Stomach emptying slows, prolonging satiety.
Neither drug forces weight loss — they make eating less feel easy rather than constantly fought against.
Mounjaro vs Wegovy
In head-to-head trials, Mounjaro tends to produce greater average weight loss:
- Mounjaro at full dose (15mg weekly) — SURMOUNT-1 trial showed average 21% body-weight reduction over 72 weeks.
- Wegovy at full dose (2.4mg weekly) — STEP-1 trial showed average 15% body-weight reduction over 68 weeks.
Individual response varies hugely. Some patients respond better to Wegovy than Mounjaro. Tolerability differs too. As an Independent Prescriber, Mohammed can switch you between products if one isn't working — you don't have to start over with another service.
NICE eligibility criteria
| BMI | Eligibility |
|---|---|
| 30 or above | Eligible (general population) |
| 27.5–29.9 | Eligible IF you have a weight-related condition (type 2 diabetes, hypertension, sleep apnoea, NAFLD, dyslipidaemia) |
| Below 27.5 | Not recommended — risks outweigh benefits at lower BMI |
For South Asian, Black African and Black Caribbean populations — a meaningful proportion of Wigston residents — NICE recommends adjusted lower BMI thresholds (BMI 27.5 instead of 30) because cardiovascular risk emerges at lower BMI in these populations.
Month-by-month: what to expect
Weeks 1–4
Modest appetite reduction. Some nausea in the first 3–5 days after each injection, worse with high-fat or large meals. Weight loss 1–3kg.
Weeks 5–8
Appetite reduction more pronounced. Most early side effects begin to settle. Weight loss typically 1–2kg per week initially, then slowing.
Months 3–6
Dose continues to escalate to maintenance (15mg Mounjaro / 2.4mg Wegovy). Cumulative weight loss typically 5–12% body weight by month 6.
Months 6–12
Weight loss continues but plateaus toward end of year 1. Many patients hit 15–20% total weight loss by month 12. Metabolic markers — HbA1c, blood pressure, cholesterol — improve substantially.
Side effects: the full picture
Most common (>10%): nausea, indigestion, constipation or diarrhoea, particularly weeks 1–8 while your body adjusts. Less common but worth knowing: gallbladder problems (rapid weight loss raises gallstone risk); pancreatitis (rare, severe abdominal pain is a red flag); thyroid effects (contraindicated in people with personal/family history of medullary thyroid cancer or MEN-2). Full prescribing information at the eMC Summary of Product Characteristics for Mounjaro KwikPen.
How much does private treatment cost?
Pricing varies by dose. We charge for the medication only — the initial consultation, monthly reviews, injection demonstration, and GLP-1 prescription itself are all included. We'll give you the full monthly figure at consultation. No subscription, no auto-billing, no contract. Stop the moment you reach your goal or anytime before.
Lifestyle alongside treatment
GLP-1 medications work best alongside, not instead of, lifestyle changes:
- Strength training 2–3x per week — preserves muscle mass during weight loss, maintains resting metabolic rate.
- Protein at every meal — 0.8–1.2g per kg target weight per day.
- Walking — 7,500–10,000 steps daily is achievable on appetite-suppressed days.
- Sleep — less than 7 hours raises appetite-stimulating ghrelin.
Getting to Welford Road from Wigston
Three miles north up the A5199 / Saffron Lane. About ten minutes by car. Free patient parking on-site. The 47 and 84 buses connect Wigston town centre to Welford Road, with stops within a 3-minute walk of the clinic. If you're coming from north Wigston (around Blaby Road), the route via the A5199 is fastest. From south Wigston (around the Royal British Legion area), Saffron Lane direct is more efficient.
NHS Tier 3 vs private
NHS Tier 3 services are excellent when you can access them, and free. They include dietitian support, group education, and sometimes GLP-1 prescribing. The catch is waiting time — most Tier 3 services have 12–24 month waits with strict BMI thresholds. If you fit and can wait, ask your GP about referral first. For everyone else — BMI 27.5–34.9 or unable to wait — private is the practical route.
What's included in your weight loss programme.
Free initial consultation, GLP-1 prescription on-site by an Independent Prescriber, monthly progress reviews. No subscription, no contract.
Free initial consultation
Mounjaro (tirzepatide)
Wegovy (semaglutide)
Independent Prescriber on-site
Monthly progress reviews
Stop anytime
Three steps from consultation to first injection.
Free consultation, prescription, monthly reviews. Stop anytime.
Free initial consultation
Prescription and first injection
Monthly reviews and dose escalation
Three miles from Wigston. Free patient parking.
Walk-in welcome Monday to Saturday. Same-day bookings available most of the time.
North up the A5199 / Saffron Lane. 10 minutes from Wigston town centre.
- Mon09:00 – 19:00
- Tue09:00 – 19:00
- Wed09:00 – 19:00
- Thu09:00 – 19:00
- Fri09:00 – 19:00
- Sat09:00 – 17:00
- SunClosed
Common questions about Mounjaro and Wegovy.
If your question isn't here, give us a call and we'll talk it through.
References for this page
Every clinical claim above is sourced from an authoritative public reference.
- 01NICE TA1026NICETirzepatide for managing overweight and obesityhttps://www.nice.org.uk/guidance/ta1026Accessed 12 May 2026
- 02NICE TA875NICESemaglutide for managing overweight and obesityhttps://www.nice.org.uk/guidance/ta875Accessed 12 May 2026
- 03MHRA Drug Safety UpdateMHRAGLP-1 receptor agonists — prescribing and safety informationhttps://www.gov.uk/drug-safety-updateAccessed 12 May 2026
- 04Electronic Medicines Compendium (eMC)MHRAMounjaro KwikPen Summary of Product Characteristicshttps://www.medicines.org.uk/emc/product/14149Accessed 12 May 2026
- 05NHSNHSObesity overview and treatment optionshttps://www.nhs.uk/conditions/obesity/Accessed 12 May 2026
- 06General Pharmaceutical CouncilGPHCRegister entry — Mohammed Kolia (Reg. 2073260)https://www.pharmacyregulation.org/registers/pharmacist/2073260Accessed 12 May 2026
Information on this page is for general guidance. Suitability for GLP-1 weight loss treatment depends on BMI, medical history, and clinical assessment. A consultation determines whether treatment is appropriate.
